ILMN - Illumina Inc
NYSE * Health Care * Life Sciences Tools & Services
$134.46
+$7.06 (+5.54%)
About Illumina Inc
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
ILMN Key Statistics
Market Cap
$20.56B
P/E Ratio
24.67
P/B Ratio
7.15
EPS
$5.45
Revenue Growth
+0.1%
Profit Margin
0.2%
Employees
8,600
How ILMN Compares to Peers
P/E Rank
#1
of 2
Margin Rank
#1
of 2
Growth Rank
#2
of 2
Size Rank
#2
of 2
Illumina Inc Company Information
- Headquarters
- California; U.S.A
- Website
- www.illumina.com
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services